← Back to Search

Prostacyclin Analogue

Iloprost for Lung Cancer Prevention

Phase 1
Waitlist Available
Led By York E Miller
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial tests if inhaling iloprost can prevent lung cancer in former smokers with abnormal cells in their mucus. The study aims to find the best dose and check for side effects. Iloprost may work by influencing genes and cell functions related to cancer. Iloprost has been studied for various lung conditions and has shown potential benefits in improving lung tissue health in former smokers.

Eligible Conditions
  • Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of clinical toxicity
Anesthetics, Inhalation
Secondary study objectives
Endobronchial brushing gene expression
Gene expression of dysplastic lesions
Chronic Obstructive Airway Disease
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm III (iloprost BID)Experimental Treatment3 Interventions
Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
Group II: Arm I (iloprost QID)Experimental Treatment3 Interventions
Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
Group III: Arm IV (placebo BID)Placebo Group3 Interventions
Patients receive placebo via inhalation using a nebulizer BID for 60 days.
Group IV: Arm II (placebo QID)Placebo Group3 Interventions
Patients receive placebo via inhalation using a nebulizer QID for 60 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloprost
2010
Completed Phase 4
~1180

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,924 Previous Clinical Trials
41,017,917 Total Patients Enrolled
York E MillerPrincipal InvestigatorNorthwestern University
1 Previous Clinical Trials

Media Library

Iloprost (Prostacyclin Analogue) Clinical Trial Eligibility Overview. Trial Name: NCT02237183 — Phase 1
Lung Cancer Research Study Groups: Arm IV (placebo BID), Arm I (iloprost QID), Arm II (placebo QID), Arm III (iloprost BID)
Lung Cancer Clinical Trial 2023: Iloprost Highlights & Side Effects. Trial Name: NCT02237183 — Phase 1
Iloprost (Prostacyclin Analogue) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02237183 — Phase 1
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top